DNA and its associated processes as targets for cancer therapy

Nature Reviews Cancer

Volumn 2, Issue 3, 2002, Pages 188-200

  Hurley, Laurence H ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALKYLATING AGENT; ANTHRAMYCIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BIZELESIN; BLEOMYCIN; CANFOSFAMIDE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACTINOMYCIN; DISTAMYCIN A; DOUBLE STRANDED DNA; DOXORUBICIN; ETOPOSIDE; GLUTATHIONE TRANSFERASE; IMATINIB; MELPHALAN; MITOMYCIN C; MITOXANTRONE; MUSTARD GAS DERIVATIVE; OLIGONUCLEOTIDE; PROTEIN; PROTEIN TMPYP4; RACHELMYCIN; SGN 15; TRABECTEDIN; TRIPLEX FORMING OLIGONUCLEOTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; CROSS LINKING REAGENT; DNA;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; BONE MARROW SUPPRESSION; CANCER; CANCER CHEMOTHERAPY; CANCER RESEARCH; CANCER THERAPY; CYTOTOXICITY; DNA BINDING; DRUG EFFICACY; DRUG RESEARCH; DRUG SPECIFICITY; DRUG TARGETING; GENE TARGETING; HUMAN; LEUKEMIA; LYMPHOMA; NAUSEA; ONCOGENE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; VOMITING; ALKYLATION; DRUG EFFECT; GENETICS; NEOPLASM;

ALKYLATION; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CROSS-LINKING REAGENTS; DNA; DNA, NEOPLASM; HUMANS; NEOPLASMS;

EID: 0036519363     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc749     Document Type: Review

References (90)

1. Slapak, C. A. & Kufe, D. W. in Harrison's Principles of Internal Medicine 14th edn (eds Isselbacher, K. J. et al.) 523-537 (McGraw-Hill, Inc. (Health Professions Div., New York, 1998).
2. Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Eng. J. Med. 344, 1031-1037 (2001).
3. Kohn, K. Beyond DNA cross-linking: history and prospects of DNA-targeted cancer treatment. Fifteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 56, 5533-5546 (1996).
4. Infield, G. B. Disaster at Bari (Macmillan, New York, 1971).
5. Ward, K. Jr. The chlorinated ethylamines: a new type of vesicant. J. Am. Chem. Soc. 57, 914-916 (1935).
6. Gilman, A. & Philips, F. S. The biological actions and therapeutic applications of β-chloroethyl amines and sulfides. Science 103, 409-415 (1946).
7. Goodman, L. S., Wintrobe, M. M., Dameshek, W., Goodman, J. J. & Gilman, A. Nitrogen mustard therapy. Use of methyl-bis(β-chloroethylamine hydrocholoride) and tris(β-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. JAMA 132, 126-132 (1946). The first report of clinical results from 67 patients treated with nitrogen mustards for Hodgkin's disease, lymphosarcoma and leukaemia. Some marked improvements were found, but the margin of safety was narrow.
8. Clark, A. S. et al. Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide. J. Med. Chem. 38, 1493-1504 (1995).
9. Goldacre, R. J., Loveless, A. & Ross, W. C. The mode of production of chromosome abnormalities by nitrogen mustard: possible role of crosslinking. Nature 163, 667-669 (1949).
10. Wang, K., Ramji, S., Bhathena, A., Lee, C. & Riddick, D. S. Glutathione S-transferases in wild-type and doxorubicin-resistant MCF-7 human breast cancer cell lines. Xenobiotica 29, 155-170 (1999).
11. Smith, S. Technology evaluation: SGN-15, Seattle Genetics Inc. Curr. Opin. Mol. Ther. 3, 295-302 (2001).
12. Syrigos, K. N. & Epenetos, A. A. Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations. Anticancer Res. 19, 605-613 (1999).
13. Dorr, R. T. & Von Hoff, D. D. Cancer Chemotherapy Handbook (Appleton & Lange, Norwalk, Connecticut, 1994).
14. Gottesfeld, J. M., Turner, J. M. & Dervan, P. B. Chemical approaches to control gene expression. Gene Expr. 9, 77-91 (2000).
15. Giovannangeli, C. & Hélène, C. Triplex-forming molecules for modulation of DNA information processing. Curr. Opin. Mol. Ther. 2, 288-297 (2000).
16. Neidle, S. The molecular basis for the action of some DNA-binding drugs. Prog. Med. Chem. 16, 151-221 (1979).
17. Minford, J. et al. Isolation of intercalator-dependent protein-linked DNA strand cleavage activity from cell nuclei and identification as topoisomerase. II. Biochemistry 25, 9-16 (1986). The protein linked to the intercalator DNA strand-cleaved product was shown to be topoisomerase II.
18. Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D., & Liu, L. F. Adriamycin-induced DNA damage mediate by mammalian DNA topoisomerase II. Science 226, 466-468 (1984). In a cell-free system, doxorubicin is shown to produce topoisomerase-II-mediated cleavage of DNA, inferring that this drug affects the breakage-reunion reaction by stabilizing the cleavable complex.
19. Henderson, D. & Hurley, L. H. Molecular struggle for transcriptional control. Nature Med. 1, 525-527 (1995).
20. Zhong, D., Pal, S. K., Wan, C. & Zewail, A. H. Femtosecond dynamics of a drug-protein complex: daunomycin with Apo riboflavin-binding protein. Proc. Natl Acad. Sci. USA 98, 11873-11878 (2001).
21. Reich, E. & Goldberg, I. H. Actinomycin and nucleic acid function. Prog. Nucleic Acid Res. Mol. Biol. 3, 183-234 (1964).
22. Muller, W. & Crothers, D. M. Studies of the binding of actinomycin and related compounds to DNA. J. Mol. Biol. 35, 251-290 (1968).
23. Sobell, H. M., Jain, S. C., Sakore, T. D. & Nordman, C. E. Stereochemistry of actinomycin-DNA binding. Nature New Biol. 231, 200-205 (1971).
24. Zimmer, C. & Wahnert, U. Nonintercalating DNA-binding ligands: specificity of the interaction and their use as tools in biophysical, biochemical and biological investigations of the genetic material. Prog. Biophys. Mol. Biol. 47, 31-112 (1986).
25. Thuong, N. & Hélène, C. Sequence specific recognition and modification of double helical DNA by oligonucleotides. Angew. Chem. Int. Ed. Engl. 32, 666-690 (1993).
26. Strobel, S. A., Doucette-Stamm, L. A., Riba, L., Houseman, D. E. & Dervan, P. B. Site specific cleavage of human chromosome 4 mediated by triple helix formation. Science 254, 1639-1642 (1991).
27. Gellert, M., Lipsett, M. N. & Davies, D. R. Helix formation by guanylic acid. Proc. Natl Acad. Sci. USA 48, 2013-2018 (1962).
28. Han, H. & Hurley, L. H. G-quadruplex DNA: a potential target for anti-cancer drug design. Trends Pharmacol. Sci. 21, 136-142 (2000).
29. Kerwin, S. M. G-quadruplex DNA as a target for drug design. Curr. Pharm. Des. 6, 441-471 (2000).
30. Sun, D. et al. Inhibition of human telomerase by a G-quadruplex-interactive compound. J. Med. Chem. 40, 2113-2116 (1997).
31. Broggini, M. & D'Incalci, M. Modulation of transcription factor-DNA interactions by anticancer drugs. Anti-Cancer Drug Des. 9, 373-387 (1994).
32. Gniazdowski, M. & Czyz, M. Transcription factors as targets of anticancer drugs. Acta Biochim. Pol. 46, 255-262 (1999).
33. Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem. 65, 635-692 (1996).
34. Pourquier, P. & Pommier, Y. Topoisomerase I-mediated DNA damage. Adv. Cancer Res. 80, 189-216 (2001).
35. Nitiss, J. L. Investigating the biological functions of DNA topoisomerase in eukaryotic cells. Biochim. Biophys. Acta 1400, 63-81 (1998).
36. Vladu, B. et al. 7- and 10-substituted camptothecins: dependence of topoisomerase I-DNA cleavable complex formation and stability on the 7- and 10-substituents. Mol. Pharmacol. 57, 243-251 (2000).
37. Pommler, Y. in Cancer Therapeutics: Experimental and Clinical Agents (ed. Teicher, B. A.) 153-173 (Humana, Totowa, New Jersey, 1997).
38. Rosenberg, B. & Camp, L. V. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205, 698-699 (1965).
39. Bellon, S. F., Coleman, J. H. & Lippard, S. J. DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry 30, 8026-8035 (1991).
40. Brown, S. J., Kellett, P. J. & Lippard, S. J. Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. Science 261, 603-605 (1993).
41. Treiber, D. K., Zhai, X., Jantzen, H.-M. & Essigmann, J. M. Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). Proc. Natl Acad. Sci. USA 91, 5672-5676 (1994). The authors introduce the idea that drugs that distort DNA, such as cisplatin, might result in high-affinity binding sites for transcriptional factors and so act as molecular decoys for them.
42. Jamieson, E. R. & Lippard, S. J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 99, 2467-2498 (1999).
43. Thompson, A. S., Sun, D. & Hurley, L. H. Monoalkylation and cross-linking of DNA by cyclopropapyrroloindoles entraps bent and straight forms of A-tract J. Am. Chem. Soc. 117, 2371-2372 (1995).
44. Sun, D. & Hurley, L. H. Cooperative bending of the 21-base-pair repeats of the SV40 viral early promoter by human Sp1. Biochemistry 33, 9578-9587 (1994).
45. Rinehart, K. L. et al. Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinate. J. Org. Chem. 55, 4512-4515 (1990).
46. Zewail-Foote, M. et al. The inefficiency of incisions of Ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent. Chem. Biol. 8, 1033-1049 (2001).
47. Garcia-Nieto, R., Manzanares, I., Cuevas, C. & Gago, F. Increased DNA binding specificity for antitumor ecteinascidin 743 through protein-DNA interactions? J. Med. Chem. 43, 4367-4369 (2000).
48. Zewail-Foote, M. & Hurley, L. H. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J. Med. Chem. 42, 2943-2497 (1999).
49. Takebayashi, Y. et al. Antiproliferative activity of Ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nature Med. 7, 961-966 (2001). The unique mechanism of action of Et-743 is shown to involve TC-NER: the drug-trapped complex results in single-stranded breaks in DNA.
50. Erba, E. et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur. J. Cancer 37, 97-105 (2001).
51. Reed, E. Platinum-DNA adduct, nucleotide excision repair, and platinum-based anti-cancer chemotherapy. Cancer Treat. Rev. 24, 331-344 (1998).
52. Jin, S., Gorfajn, B., Faircloth, G. & Scotto, K. W. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc. Natl Acad. Sci. USA 97, 6775-6779 (2000).
53. Synold, T. W., Dussault, I. & Forman, B. M. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nature Med. 7, 584-590 (2001).
54. Minuzzo, M. et al. Interference of transcriptional activation by the antineoplastic drug Ecteinascidin-743. Proc. Natl Acad. Sci. USA 97, 6780-6784 (2000).
55. Hansen, M. & Hurley, L. H. Pluramycins. Old drugs having modern friends in structural biology. Acc. Chem. Res. 29, 249-258 (1996).
56. Hélène, C. Sequence-selective recognition and cleavage of double-helical DNA. Curr. Opin. Biotechnol. 4, 29-36 (1993).
57. 2 complex by two-dimensional NMR. Proc. Natl Acad. Sci. USA 86, 5723-5727 (1989). The first report of the side-by-side or 2:1 ligand:DNA complex that was determined by nuclear magnetic resonance. This was the clue that the Dervan lab needed to explain the unexpected footprinting pattern observed in gels in which the same 2:1 antiparallel side-by-side dimer was present (see reference 90).
58. Dervan, P. B. & Bürli, R. W. Sequence-specific DNA recognition by polyamides. Curr. Opin. Biol. 3, 688-693 (1999).
59. Trauger, J. W., Baird, E. E., Mrksich, M. & Dejan, P. B. Extension of sequence-specific recognition in the minor groove of DNA by pyrrole-imidazole polyamides to 9-13 base pairs. J. Am. Chem. Soc. 118, 6160-6166 (1996).
60. Swalley, S. E., Baird, E. E. & Dervan, P. B. A pyrrole-imidazole polyamide motif for recognition of eleven base pair sequences in the minor groove of DNA. Chem. Eur. J. 3, 1600-1607 (1997).
61. Wurtz, N. R. & Dejan, P. B. Sequence specific alkylation of DNA by hairpin pyrrole-imidazole polyamide conjugates. Chem. Biol. 7, 153-161 (2000).
62. Zhi-Fu, T., Fujiwara, T., Saito, I. & Sugiyama, H. Rational design of sequence-specific DNA alkylating agents based on duocarmycin A and pyrrole-imidazole hairpin polyamides. J. Am. Chem. Soc. 121, 4961-4967 (1999).
63. Kohn, K. W., Hartley, J. A. & Mattes, W. B. Mechanisms of DNA sequence selective alkylation of guanine-N7 positions by nitrogen mustards. Nucleic Acids Res. 15, 10531-10549 (1987). The first critical insight based on experimental data for the origin of the sequence specificity of nitrogen mustards.
64. Seaman, F. & Hurley, L. H. Molecular basis for the DNA sequence selectivity of ecteinascidin 736 and 743: evidence for the dominant role of direct readout via hydrogen bonding. J. Am. Chem. Soc. 120, 13028-13041 (1998).
65. Tomasz, M. et al. Isolation and structure of a covalent cross-link adduct between mitomycin C and DNA. Science 235, 1204-1208 (1987). The long-sought-after structure of crosslinked DNA with mitomycin C.
66. Nielsen, P. E. Peptide nucleic acids as therapeutic agents. Curr. Opin. Struct. Biol. 9, 353-357 (1999).
67. Lohse, J. Dahl, O. & Nielsen, P. E. Double duplex invasion by peptide nucleic acid: a general principle for sequence-specific targeting of double stranded DNA. Proc. Natl Acad. Sci. USA 96, 11804-11808 (1999).
68. Majumdar, A. et al. Targeted gene knockout mediated by triple helix forming oligonucleotides. Nature Genet. 20, 212-214 (1998). A proof of principle that triple-helix technology can deliver the oligomer to the anticipated site in genomic DNA.
69. Giovannangeli, C. & Hélène, C. Triplex technology takes off. Nature Biotechnol. 18, 1245-1256 (2000).
70. Arimondo, P. B. et al. Design and optimization of camptothecin conjugates of triple helix-forming oligonucleotides for sequence - specfic DNA cleavage by topoisomerase I. J. Biol. Chem. 277, 3132-3140 (2002).
71. Keniry, M. A. Quadruplex structures in nucleic acids. Biopolymers (Nucleic Acid Sci.) 56, 123-146 (2001).
72. Gehring, K., Leroy, J. L. & Gueron, M. A tetrameric DNA structure with protonated cytosine-cytosine base pairs Nature 363, 561-565 (1993).
73. Fang, G. & Cech, T. R. The subunit of Oxtricha telomere-binding protein promotes G-quartet formation by telomeric DNA. Cell 74, 875-885 (1993).
74. Sun, H., Bennett, R. J. & Maizels, N. The Saccharomyces cerevisiae Sgs1 helicase efficiently unwinds G-G paired DNAs. Nucleic Acids Res. 27, 1978-1984 (1999).
75. Damm, D. et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J. 20, 6958-6968 (2001). The first small-molecule catalytic inhibitor of telomerase to be described in which telomere shortening and senescence characteristics were shown. The long time period that is required to produce these effects will be a challenge for clinical use.
76. Duan, W. et al. Design and synthesis of fluoroquinophenoxazines that interact with G-quadruplexes and their biological effects. Mol. Cancer Ther. 1, 103-120 (2001).
77. Hemann, M. T., Strong, M. A., Hao, L.-Y. & Greider, C. W. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell 107, 67-77 (2001).
78. Simonsson, T., Pecinka, P. & Kubista, M. DNA tetraplex formation in the control region of c-myc. Nucleic Acids Res. 26, 1167-1172 (1998).
79. Bazarov, A. V. et al. A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to ras and raf transformation. Cancer Res. 61, 1178-1186 (2001).
80. Waters, J. S. et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 18, 1812-1823 (2000). The first demonstration of the clinical use of antisense therapy in treating cancer through downregulation of an oncogene.
81. Woynarowski, J. M., Trevino, A. V., Rodriguez, K. A., Hardies, S. C. & Benham, C. J. AT-rich islands in genomic DNA as a novel target for AT-specific DNA-reactive antitumor drugs. J. Biol. Chem. 276, 40555-40566 (2000).
82. Janssen, S., Cuvier, O., Müller, M. & Laemmli, U. K. Specific gain- and loss-of-function phenotypes induced by satellite-specific DNA-binding drugs fed to Drosophila melanogaster. Mol. Cell 6, 1013-1024 (2000). Proof of principle that polyamides can target A•T regions in a whole organism after oral administration.
83. Kohn, K. W., Shao, R. G. & Pommier, Y. How do drug-induced topoisomerase I-DNA lesions signal to the molecular interaction network that regulates cell cycle checkpoints, DNA replication, and DNA repair? Cell Biochem. Biophys. 33, 175-180 (2000).
84. Westin, L., Blomquist, P., Milligan, J. F. & Wrange, O. Triple helix DNA alters nucleosomal histone-DNA interactions and acts as a nucleosome barrier. Nucleic Acids Res. 23, 2184-2191 (1995).
85. Gottesfeld, J. M. et al. Sequence-specific recognition of DNA in the nucleosome by pyrrole-imidazole polyamides. J. Mol. Biol. 309, 615-629 (2001).
86. Portugal, J. Drug interactions with nucleosomes and chromatin. Methods Enzymol. 340, 503-518 (2001).
87. Han, H., Langley, D. R., Rangan, A. & Hurley, L. H. Selective interactions of cationic porphyrins with G-quadruplex structures. J. Am. Chem. Soc. 123, 8902-8913 (2001).
88. Rangan, A., Fedoroff, O. Y. & Hurley, L. H. Induction of duplex to G-quadruplex transition in the c-myc promoter region by a small molecule. J. Biol. Chem. 276, 4640-4646 (2001).
89. Bremer, R. E., Baird, E. E. & Dejan, P. B. Inhibition of major-groove-binding proteins by pyrrole-midazole polyamides with an Arg-Pro-Arg positive patch. Chem. Biol. 5, 119-133 (1998).
90. Dervan, P. B. Molecular recognition of DNA by small molecules. Bioorg. Med. Chem. 9, 2215-2236 (2001).